Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 16,085 | $0.00 Strike: $25.54 | $0.00 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · derivative · entry 5 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 16,085 shares Expires 2016-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 20,000 | $64.70 | $1,293,960.00 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · nonDerivative · entry 4 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,978 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 64.32 to 65.20. The price reported above represents the weighted average sales price. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 948 | $33.70 | $31,947.60 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · nonDerivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 2,967 | $33.70 | $99,987.90 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 19:59 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 16,085 | $25.54 | $410,810.90 |
DisclosureSEC source: 0001140361-16-082160 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 21:30 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,000 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-081739 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,033 Underlying: ResMed Common Stock · 6,000 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 21:30 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,000 | $63.95 | $383,718.00 |
DisclosureSEC source: 0001140361-16-081739 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,061 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $63.64 to $64.28. The price reported above reflects the weighted average sale price. Read SEC document |
| October 03, 2016 Filed Oct 4, 2016 21:30 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,000 | $33.70 | $202,200.00 |
DisclosureSEC source: 0001140361-16-081739 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 15, 2016 Filed Sep 17, 2016 01:15 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 5,975 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-080106 · doc1.xml · derivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,275 Underlying: ResMed Commmon Stock · 5,975 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| September 15, 2016 Filed Sep 17, 2016 01:15 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 5,975 | $64.84 | $387,419.00 |
DisclosureSEC source: 0001140361-16-080106 · doc1.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,806 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 15, 2016 Filed Sep 17, 2016 01:15 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 5,975 | $33.70 | $201,357.50 |
DisclosureSEC source: 0001140361-16-080106 · doc1.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F1 · balance_after: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 16:43 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,000 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-16-079165 · doc1.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,033 Underlying: ResMed Common Stock · 6,000 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/4 per year. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 16:43 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 6,000 | $67.18 | $403,050.00 |
DisclosureSEC source: 0001140361-16-079165 · doc1.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,061 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $66.99 to $67.36. The price reported above reflects the weighted average sale price. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 16:43 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 6,000 | $33.70 | $202,200.00 |
DisclosureSEC source: 0001140361-16-079165 · doc1.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 16:44 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResmed Stock Option Plan · Derivative | 20,000 | $0.00 Strike: $25.54 | $0.00 |
DisclosureSEC source: 0001140361-16-079166 · doc1.xml · derivative · entry 3 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,085 Underlying: ResMed Common Stock · 20,000 shares Expires 2016-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vested 1/4 per year. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 16:44 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 20,000 | $67.29 | $1,345,760.00 |
DisclosureSEC source: 0001140361-16-079166 · doc1.xml · nonDerivative · entry 2 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,978 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from 66.97 to 67.43. The price reported above represents the weighted average sales price. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 16:44 UTC |
FARRELL PETER CDirector
|
Exercise / conversionResMed Common Stock | 20,000 | $25.54 | $510,800.00 |
DisclosureSEC source: 0001140361-16-079166 · doc1.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.